25 results
8-K
EX-3.1
MDGL
Madrigal Pharmaceuticals Inc
16 Jun 23
Amendments to Articles of Incorporation or Bylaws
6:54pm
8-K
EX-3.1
MDGL
Madrigal Pharmaceuticals Inc
23 Dec 22
Madrigal Pharmaceuticals Announces $300+ Million in Financing Events to Advance Resmetirom Program
7:00am
SC 13D/A
EX-3
Bay City Capital LLC
13 Dec 19
Madrigal Pharmaceuticals, Inc.
5:14pm
8-K
EX-3.1
MDGL
Madrigal Pharmaceuticals Inc
21 Jun 17
Madrigal Pharmaceuticals Announces $35 Million Private Placement Offering
12:00am
10-K
2016 FY
EX-3.1
MDGL
Madrigal Pharmaceuticals Inc
Annual report
31 Mar 17
12:00am
8-K
EX-3.1
a1s1i8r
22 Jul 16
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
EX-3.2
eowo82c3wcidraw
22 Jul 16
Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
DEFA14A
EX-3.1
bibnke8 qr2rc
14 Apr 16
Additional proxy soliciting materials
12:00am
8-K
EX-3.1
zpmhwb pe93f
14 Apr 16
Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company
12:00am
8-K
EX-3.1
nz4tc
17 Jun 13
Amendments to Articles of Incorporation or Bylaws
12:00am